Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

類似資料

• Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
  著者:: Wetzler, M, 等
  出版事項: (2015)
• Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
  著者:: Nicolini, Franck E., 等
  出版事項: (2013)
• Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib
  著者:: Cortes, Jorge E., 等
  出版事項: (2013)
• Final Analysis of Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML): 24-Month Minimum Follow-Up Results
  著者:: Cortes, Jorge, 等
  出版事項: (2015)
• Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate
  著者:: Shen, Ann Q., 等
  出版事項: (2014)